ବ୍ୟବହାରକାରୀ:Doc James/Test

Doc James/Test

Clinical data
Pronunciation	/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade names	Votrient
AHFS/Drugs.com	monograph
MedlinePlus	a610013
data	EU EMA: yes US DailyMed: Pazopanib
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	By mouth (tablets)
Drug class	Tyrosine kinase inhibitor
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	21% (14–39%)
Protein binding	>99.5%
Metabolism	Liver: CYP3A4 (major), 1A2 and 2C8 (minor)
Elimination half-life	30.9±4 hours
Excretion	Faeces (primary), urine (<4%)
Identifiers
IUPAC name 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide
Chemical and physical data
Formula	C21H23N7O2S
Molar mass	୪୩୭.୫୨ g·mol−1
3D model (JSmol)	Interactive image
SMILES O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C
InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H Y Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Pazopanib, sold under the brand name Votrient, is a medication used to treat renal cell carcinoma (RCC) and certain soft tissue sarcoma. In RCC it is used when other treatments have failed. It is taken by mouth.

Common side effects include diarrhea, high blood pressure, white hair, nausea, tiredness, abdominal pain, low blood cells, and liver problems. Other side effects may include low thyroid, QT prolongation, bleeding, blood clots, and gastrointestinal perforation. Use during pregnancy may harm the baby. It is a tyrosine kinase inhibitor.

Pazopanib was approved for medical use in the United States in 2009. In Europe it received conditional approval in 2010 and full approval in 2013. In the United Kingdom it costs the NHS about £2,250 per month as of 2021. In the United States this amount costs about 14,200 USD.